| 1 |
33143745 | Treatment- and population-specific genetic risk factors for anti-drug antibodies against interferon-beta: a GWAS. | 2020 Nov 4 |
1 |
| 2 |
29066027 | Interferon-beta specific T cells are associated with the development of neutralizing antibodies in interferon-beta treated multiple sclerosis patients. | 2018 Mar |
2 |
| 3 |
28418769 | Persistency of Neutralizing Anti-Interferon-β Antibodies in Patients with Multiple Sclerosis Treated with Subcutaneous Interferon-β Depends on Antibody Titers, IgG Subclasses, and Affinity Maturation. | 2017 Jul |
3 |
| 4 |
28729851 | Development and Validation of an Enzyme-Linked Immunosorbent Assay for the Detection of Binding Anti-Drug Antibodies against Interferon Beta. | 2017 |
2 |
| 5 |
27806057 | Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis. | 2016 |
4 |
| 6 |
23770627 | Immunoglobulin G1 and immunoglobulin G4 antibodies in multiple sclerosis patients treated with IFNβ interact with the endogenous cytokine and activate complement. | 2013 Aug |
1 |